According to the Zhītōng Finance APP, Trinity Biotech (TRIB.US) saw its stock price rise by 44% after hours on Monday. Prior to this, the diagnostic company had raised its sales guidance for 2024 and stated that it was increasing production capacity.
Trinity Biotech stated that due to increased demand, the company has expanded the production capacity of its TrinScreen HIV testing product and raised its sales forecast for this product in 2024 from $8 million to $10 million.
According to a statement, the company has also increased the production capacity of its FlexTrans virus transport medium in anticipation of increased demand due to an outbreak of monkeypox.
The World Health Organization recently announced that an outbreak of monkeypox, due to a more easily transmissible variant of the virus, constitutes an &#34;internationally concerning public health emergency.&#34;
Developers of monkeypox vaccines include Tonix Pharmaceuticals (TNXP.US), Bavarian Nordic (BVNRY.US), and GeoVax Labs (GOVX.US), while Emergent BioSolutions (EBS.US) has received approval for a vaccine and therapy targeting smallpox (which is related to the monkeypox virus).
Suppliers of monkeypox testing products and services include LabCorp (LH.US), Quest Diagnostics (DGX.US), Co-diagnostics (CODX.US), Roche (RHHBY.US), Abbott (ABT.US), and Applied DNA Sciences (APDN.US)

TRIB

SIGA

GOVX

CMRX

Trinity Biotech's stock price rose by 44% after hours on Monday, as the company raised its sales guidance for 2024 and expanded production capacity for HIV testing and smallpox products. It is expected that sales of HIV testing products will increase from $8 million to $10 million. Additionally, the outbreak of smallpox has prompted the company to increase the production capacity of virus transport media. Smallpox has been declared an international public health emergency by the World Health Organization

- Trinity Biotech's (TRIB.US) stock price surged by 44% after hours on Monday following the company's announcement of raising its 2024 sales guidance and increasing production capacity, particularly for its TrinScreen HIV testing product, expecting sales to reach $10 million, up from $8 million. 
- The company also expanded production of its FlexTrans virus transport medium in anticipation of increased demand due to an outbreak of monkeypox, declared an "international public health emergency" by the WHO due to a more easily transmissible virus variant.
- Key players in monkeypox vaccines and treatments include Tonix Pharmaceuticals (TNXP.US), Bavarian Nordic (BVNRY.US), GeoVax Labs (GOVX.US), and Emergent BioSolutions (EBS.US) with an approved vaccine and therapy for smallpox (related to the monkeypox virus). Suppliers of monkeypox testing products and services include LabCorp (LH.US), Quest Diagnostics (DGX.US), Co-diagnostics (CODX.US), Roche (RHHBY.US), Abbott (ABT.US), and Applied DNA Sciences (APDN.US).

Zhitong

Trinity Biotech

Siga Tech

GeoVax Labs

Inovio Pharma

Emergent Biosolutions

Chimerix

US Stock Market News | Monkeypox + HIV Product Demand Increases, Trinity Biotech Soars 44% After Hours